Abstract
While anti-PD1 therapy has transformed the treatment landscape for various malignancies, the impact of chronic Hepatitis B virus (HBV) infection on treatment efficacy in non-liver cancers has remained poorly understood. This study investigated the clinical outcomes and immunological mechanisms underlying the response to anti-PD1 therapy in HBV-positive (HBV+) versus HBV-negative (HBV-) non-liver cancer patients. Through a multicenter retrospective analysis and single-cell RNA sequencing (scRNA-seq), the researchers demonstrate that HBV+ patients achieve significantly better clinical outcomes. This enhanced response appears to be driven by a higher baseline of "rechargeable" exhausted T cells and increased antigen presentation capacity in B cells following treatment.
Introduction
Immune checkpoint blockade (ICB), particularly anti-PD1 therapy, has become a cornerstone of modern oncology. However, patient response remains heterogeneous. Historically, patients with chronic HBV infection were often excluded from clinical trials for non-liver cancers due to concerns regarding viral reactivation or unpredictable immune-related adverse events (irAEs). Given the high global prevalence of HBV, understanding its influence on the immune microenvironment of non-liver malignancies is critical. This study explores the counterintuitive hypothesis that the chronic immune stimulation provided by HBV might actually prime the immune system for a more robust response to checkpoint inhibition.
Methods
The researchers conducted a multicenter retrospective study involving 84 non-liver cancer patients (35 HBV+, 49 HBV-) treated with anti-PD1 therapy between 2018 and 2022. To ensure comparability, patients were matched for cancer type, age, and gender.
To investigate the underlying cellular mechanisms, single-cell RNA sequencing (scRNA-seq) was performed on peripheral blood mononuclear cells (PBMCs) from three patients with esophageal squamous cell carcinoma (ESCC)—one HBV- and two HBV+—at pre- and post-treatment time points. A total of 44,253 individual immune cells were analyzed. The study also utilized a "Population Change Index" (PopIndex) to quantify shifts in immune cell subsets and validated findings using external datasets, including The Cancer Genome Atlas (TCGA) and previously published scRNA-seq data.
Results
Clinical Efficacy and Safety
The clinical analysis revealed a significant advantage for HBV+ patients. The Objective Response Rate (ORR) was 42.86% in the HBV+ group compared to 14.29% in the HBV- group. Statistical analysis showed that HBV+ patients had 4.41 times higher odds of responding to anti-PD1 therapy (95% CI: 1.43–14.99). Importantly, the therapy was found to be safe; there was no significant increase in irAEs in the HBV+ cohort compared to the HBV- cohort, suggesting that chronic HBV status does not preclude the safe use of ICB in non-liver cancers.
Mechanistic Insights: The Paradox of Exhaustion
Single-cell analysis provided a potential explanation for the superior outcomes in HBV+ patients. The researchers observed that HBV+ patients had a higher fraction of "Exhaustion-high" CD8+ T cells ($Exhaustion^{hi} T$) at baseline. While exhaustion is typically associated with reduced effector function, in the context of ICB, these cells represent a pool of highly suppressed but "rechargeable" lymphocytes. The transition from an exhausted state to a cytotoxic effector state was more pronounced in HBV+ responders following anti-PD1 therapy.
Multi-lineage Immune Response
The study also highlighted the role of B cells. Post-treatment, B cells in HBV+ patients exhibited a significant increase in MHC II expression, indicating enhanced antigen presentation capacity. This suggests that the benefits of anti-PD1 therapy in the context of HBV infection involve a coordinated response across multiple immune lineages, not just CD8+ T cells.
Identification of a Potential Biomarker
A specific subset of CD8+ effector T cells, characterized by high expression of $CX3CR1$ ($CX3CR1^{high} T_{EFF}$), was identified as a key player. This subset was significantly enriched in HBV+ responders. Conversely, $CX3CR1^{low}$ cells were associated with poorer prognosis in external TCGA datasets, suggesting that $CX3CR1$ expression could serve as a valuable biomarker for predicting ICB response.
Discussion
These findings suggest that the chronic immune pressure exerted by HBV infection induces a state of "primed" immunosuppression. This state, characterized by a high density of exhausted but reversible T cells, paradoxically makes the immune system more responsive to the reinvigorating effects of anti-PD1 therapy. This study challenges the traditional view of chronic viral infection as a purely negative factor in cancer immunotherapy and suggests that viral status should be considered in patient stratification.
Conclusion
Anti-PD1 therapy is both safe and more effective in HBV+ non-liver cancer patients compared to their HBV- counterparts. The enhanced efficacy is likely due to a more robust "recharging" of the immune system from a baseline of HBV-induced exhaustion. Future prospective trials are needed to validate these findings and further explore the potential of viral-induced immune signatures as predictive biomarkers in oncology.
Summary updated